NCCM
ASMB icon

Nine Chapters Capital Management’s Assembly Biosciences ASMB Stock Holding History

Nine Chapters Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-477
Closed -$37K – 986
2014
Q2 		$37K Buy
+477
New +$33.8K ﹤0.01% 911

Other funds holding ASMB

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nine Chapters Capital Management's ASMB Position: Q3 2014 in Review

Nine Chapters Capital Management sold out of Assembly Biosciences (ASMB) in Q3 2014, closing a stake of 477 shares — an estimated $37K sold.

Nine Chapters Capital Management first reported a position in ASMB in Q2 2014 and held it in 1 quarter. The position peaked at $37K in Q2 2014. 22 funds tracked by Wall St. Rank hold ASMB as of Q3 2014.

  • Nine Chapters Capital Management reported no remaining Assembly Biosciences position as of Q3 2014 after selling out during the quarter.
  • Nine Chapters Capital Management sold 477 Assembly Biosciences shares in Q3 2014, an estimated $37K.
  • Nine Chapters Capital Management first reported a position in Assembly Biosciences in Q2 2014 and held it in 1 quarter.
  • Nine Chapters Capital Management's Assembly Biosciences position peaked at $37K in Q2 2014.
  • 22 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2014.

Based on Nine Chapters Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.